In glioma patients, in fact, the expression of O6-methylguanine-DNA methyltransferase (MGMT), an enzyme involved in alkylating agent-induced DNA damage repair, is predictive of response to the treatment with carmustine and temozolomide. This evidence concerns the gene MGMT and central nervous system cancer.